11.05
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché ATRA Giù?
Forum
Previsione
Atara Biotherapeutics Inc Borsa (ATRA) Ultime notizie
What analysts say about Atara Biotherapeutics Inc. stockMarket-leading capital gains - Autocar Professional
What drives Atara Biotherapeutics Inc. stock priceExplosive capital appreciation - PrintWeekIndia
FDA accepts Atara’s BLA for tab-cel with priority review By Investing.com - Investing.com Nigeria
FDA accepts Atara’s BLA for tab-cel with priority review - Investing.com
Atara gets FDA priority review for Tabelecleucel application - Seeking Alpha
FDA Accepts Atara Biotherapeutics' BLA for Tabelecleucel (ATRA) | ATRA Stock News - GuruFocus
Atara Biotherapeutics stock jumps after FDA accepts BLA for tab-cel - Investing.com Australia
Atara Biotherapeutics Announces U.S. FDA Acceptance and Priority - GuruFocus
FDA Accepts Atara Biotherapeutics' BLA for Tabelecleucel | ATRA Stock News - GuruFocus
Atara Biotherapeutics Announces U.S. FDA Acceptance and Priority Review of the Biologics License Application for Tabelecleucel (Tab-cel®) for the Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease - Yahoo Finance
Innovation Ltd Panacea Buys 19,335 Shares of Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Stock - Defense World
Atara Biotherapeutics Inc. Stock Analysis and ForecastHigh-profit trading signals - Autocar Professional
Atara gains after insider purchase - MSN
Is Atara Biotherapeutics Inc. a good long term investmentConsistent triple-digit returns - jammulinksnews.com
Atara Biotherapeutics (ATRA) Shares Surge After Insider Purchase - GuruFocus
Atara stock gains after insider purchase (ATRA:NASDAQ) - Seeking Alpha
(ATRA) Trading Advice - news.stocktradersdaily.com
How Atara Biotherapeutics Inc. stock performs during market volatilityDaily Breakout Picks - Newser
Why Atara Biotherapeutics Inc. stock attracts strong analyst attentionFree Discussion Group - Newser
What makes Atara Biotherapeutics Inc. stock price move sharplyFree Consultation - Newser
Pierre Fabre Pharmaceuticals, Inc. Announces Transfer of Investigational New Drug Application for Tabelecleucel from Atara Biotherapeutics, Inc. - PR Newswire
Major FDA Development: Pierre Fabre Assumes Control of Atara's EBV Cell Therapy Program After BLA Resubmission - Stock Titan
Atara Biotherapeutics Resubmits BLA for Tab-cel to FDA - TipRanks
Atara Biotherapeutics Provides Regulatory and Business Updates on Tabelecleucel (Tab-cel®) | ATRA Stock News - GuruFocus
Atara Biotherapeutics provides regulatory and business updates on tabelecleucel (tab-cel) - MarketScreener
Atara resubmits tabelecleucel BLA to FDA for EBV-positive PTLD By Investing.com - Investing.com Canada
Atara resubmits tabelecleucel BLA to FDA for EBV-positive PTLD - Investing.com
Atara Biotherapeutics Provides Regulatory and Business Updates on Tabelecleucel (Tab-cel - Business Wire
(ATRA) Technical Data - news.stocktradersdaily.com
We Might See A Profit From Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Soon - simplywall.st
Atara Biotherapeutics, Inc.(NasdaqGS: ATRA) added to Russell Microcap Growth Index - MarketScreener
Layoff Tracker: Gilead Cuts 36 Employees in California - BioSpace
Atara Biotherapeutics Holds Annual Stockholders Meeting - TipRanks
Long Term Trading Analysis for (ATRA) - news.stocktradersdaily.com
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):